Table 2.
Basic characteristics of the included studies (CCRT-CCT vs. CCRT alone group).
| Author | Year | Stage | ESCC/EAC | CCRT-CCT/CCRT alone | Radiation dose (Gy) | Current chemotherapy regimen | CCT regimen | The cycles of CCT | Quality evaluation |
|---|---|---|---|---|---|---|---|---|---|
| Wu et al. (15) | 2017 | I–III | 209/0 | 67/142 | ≥50.4 | PF | PF/ND/DP | 2 | 4 |
| Chen et al. (16) | 2018 | II–III | 524/0 | 262/262 | 50.4–66 | PF | PF | 2 | 4 |
| Chen et al. (17) | 2018 | II–IVB | 187/0 | 89/98 | 50–66 | PF/TP | PF/TP | 2 (1–4) | 4 |
| Chen et al. (18) | 2018 | I–IV | 124/0 | 65/59 | 50–74 | PF/PP | PF/P | 2–4 | 4 |
| Koh et al. (19) | 2020 | I–III | 73/0 | 56/17 | 50–70 | PF/P/F | PF/P/F | – | 4 |
| Zhang et al. (20) | 2020 | I–III | 222/0 | 113/109 | 50.4–66 | LFP/PF/TP | LFP/PF/TP | 1–4 | 4 |
ESCC, esophageal squamous cell carcinoma; EAC, esophageal adenocarcinoma; P, cisplatin; F, fluorouracil; PF, cisplatin plus fluorouracil; DP, docetaxel plus cisplatin; ND, nedaplatin plus cisplatin; PP, paclitaxel plus cisplatin; LFP, cisplatin plus 5-fluorouracil plus calcium folinate; TP, cisplatin plus paclitaxel; m, months; CCT, consolidation chemotherapy; CCRT, concurrent chemoradiotherapy.